AIM: £4.88 (+0.02) | Nasdaq: $31.75 (-0.65)
News Archive

Our latest announcements or presentations are available by selecting the desired News Type.

Announcements can be further filtered by topic using the News Topic check boxes.

 

The full text of all announcements are available for download in the form of PDF files.  For convenience, the text of some announcements have been partially or fully rendered as web pages.  Should any inconsistencies exist, the PDF version shall prevail.

News Type
Presentations
RNS Announcements
News Topics
Commercial Platform
Group
Innovation Platform
Regulatory Notice
1
2345678910111213
found Documents: 601
Presentations, Scientific Publications | 21 Sep 2020

The Lancet Oncology: Surufatinib SANET-p phase 3 study
Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study Jianming Xu*, Lin Shen*, Chunmei Bai*, Wei Wang*, Jie Li, Xianjun Yu, Zhiping Li, Enxiao Li, Xianglin Yuan, Yihe
Read More
Presentations, Scientific Publications | 21 Sep 2020

The Lancet Oncology: Surufatinib SANET-ep phase 3 study
Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study Jianming Xu*, Lin Shen*, Zhiwei Zhou, Jie Li, Chunmei Bai, Yihebali Chi, Zhiping Li, Nong Xu, Enxiao Li, T
Read More
Presentations, Scientific Publications | 20 Sep 2020

ESMO2020: Surufatinib for patients with advanced pancreatic NET (SANET-p)
Title: Surufatinib (S) for patients (Pts) with advanced pancreatic neuroendocrine tumors (SANET-p): a randomized, double-blind, placebo (P)-controlled Phase III trial (NCT02589821) Lead Author: Jianming Xu, Head of the Department of Gast
Read More
Download Presentation (PDF)
Innovation Platform, Press Releases, RNS Announcements | 20 Sep 2020

Chi-Med Highlights Surufatinib Phase III Results in Neuroendocrine Tumors at ESMO 2020 and Publications in The Lancet Oncology
  ― Phase III SANET-p demonstrated surufatinib reduces the risk of disease progression or death by 51% in patients with pancreatic neuroendocrine tumors (“NET”) ―   ― SANET-p results complement previously presented positive Pha
Read More
Download Press Release (PDF)
Presentations, Scientific Publications | 18 Sep 2020

ESMO2020: Phase1/1b Trial of Fruquintinib in Patients with Advanced Solid Tumors
Title: Phase (Ph) 1/1b Trial of Fruquintinib (Fru) in Patients (Pts) with Advanced Solid Tumors: Preliminary Results of the Dose Expansion (Exp) Cohort in Refractory Metastatic Colorectal Cancer (mCRC) Lead Author: N. Arvind Dasari, Asso
Read More
View Poster (PDF)
Presentations, Scientific Publications | 18 Sep 2020

ESMO2020: SANET-ep study subgroup analysis by Ki-67 and primary tumor origins
Title: Subgroup analysis by Ki-67 and primary tumor origins of the randomized, placebo-controlled phase 3 study of surufatinib in advanced well-differentiated extrapancreatic neuroendocrine tumors (SANET-ep) Lead Author: Zhiwei Zhou, Dir
Read More
View Poster (PDF)
Innovation Platform, Press Releases, RNS Announcements | 17 Sep 2020

Chi-Med Announces Second NDA Acceptance in China for Surufatinib in Pancreatic Neuroendocrine Tumors
Hong Kong, Shanghai, & Florham Park, NJ: Thursday, September 17, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that its New Drug Application (“NDA”) for surufatinib for the treatment of patients with
Read More
Download Press Release (PDF)
Innovation Platform, Press Releases, RNS Announcements | 4 Sep 2020

Chi-Med Initiates FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer
Hong Kong, Shanghai, & Florham Park, NJ: Friday, September 4, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) has initiated FRESCO-2, a Phase III registration study of fruquintinib for the treatment of patients with metas
Read More
Download Press Release (PDF)
Innovation Platform, Press Releases, RNS Announcements | 3 Sep 2020

Chi-Med Initiates a Phase II Trial of HMPL-453 in Patients with Advanced Intrahepatic Cholangiocarcinoma in China
Hong Kong, Shanghai, & Florham Park, NJ: Thursday, September 3, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) has initiated a Phase II study of HMPL-453, its novel small molecule inhibitor targeting fibroblast growth fa
Read More
Download Press Release (PDF)
Corporate presentations, Presentations | 31 Aug 2020

Corporate Presentation
Download Presentation (with Appendix) (PDF)Download Chinese Presentation (PDF)
Regulatory Notice, RNS Announcements | 28 Aug 2020

Total Voting Rights
London: Friday, August 28, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at August 28, 2020, the issued share capital of Chi-Med consisted of 710,594,765 ordinary shares of US$0.10 each, w
Read More
View Announcement (PDF)
Innovation Platform, Press Releases, RNS Announcements | 24 Aug 2020

Chi-Med Highlights Clinical Data to be Presented at the Upcoming ESMO Virtual Congress 2020
Hong Kong, Shanghai, & Florham Park, NJ: Monday, August 24, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that new and updated analyses on the studies of surufatinib and fruquintinib will be presented
Read More
Download Press Release (PDF)
Regulatory Notice, RNS Announcements | 12 Aug 2020

Grant of Share Options under Share Option Scheme
Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, August 12, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) announces that on August 11, 2020, it granted share options under the Share Option Scheme conditionally adopte
Read More
View Announcement (PDF)
Innovation Platform, Press Releases, RNS Announcements | 10 Aug 2020

Chi-Med Plans to Submit Marketing Authorization Application for Surufatinib Following Scientific Advice from EMA’s CHMP
Hong Kong, Shanghai, & Florham Park, NJ: Monday, August 10, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that it received scientific advice from the European Medicines Agency's (“EMA”) Committee for
Read More
Download Press Release (PDF)
Group, RNS Announcements | 30 Jul 2020

Chi-Med Reports 2020 Interim Results and Provides Updates on Key Clinical Programs
– Strong global pipeline progress – three U.S. FDA1 Fast Track Designations; surufatinib U.S. NDA2 preparations underway; and initiation of global Phase III for fruquintinib –  – Two further NDAs submitted in China – savolitinib in
Read More
View Announcement (PDF)
Regulatory Notice, RNS Announcements | 30 Jul 2020

Block Admission Application
London: Thursday, July 30, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces an application has been made to the London Stock Exchange plc for a block admission of 30,221,458 ordinary shares, par value of US$0.1
Read More
Download Press Release (PDF)
Innovation Platform, Press Releases, RNS Announcements | 28 Jul 2020

Chi-Med and Lilly to Collaborate in Commercializing Elunate® in China
Hong Kong, Shanghai, & Florham Park, NJ: Tuesday, July 28, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) and Eli Lilly and Company (“Lilly”) today announce an amendment to the 2013 License and Collaboration Agreeme
Read More
Download Press Release (PDF)
Innovation Platform, Press Releases, RNS Announcements | 28 Jul 2020

Chi-Med’s NDA for Savolitinib in Non-Small Cell Lung Cancer Granted Priority Review in China
Hong Kong, Shanghai & Florham Park, NJ: Tuesday, July 28, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announced that the China National Medical Products Administration (“NMPA”) has granted Priority Review st
Read More
Download Press Release (PDF)
Innovation Platform, Press Releases, RNS Announcements | 24 Jul 2020

Chi-Med Initiates a Phase I Trial of IDH1/2 Dual Inhibitor in Patients with Hematological Malignancies in China
  — HMPL-306 is the ninth innovative oncology drug candidate discovered in house by Chi-Med —   Hong Kong, Shanghai & Florham Park, NJ: Friday, July 24, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) has in
Read More
Download Press Release (PDF)
Regulatory Notice, RNS Announcements | 8 Jul 2020

TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hutch
Read More
View Announcement (PDF)
Regulatory Notice, RNS Announcements | 7 Jul 2020

TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hutch
Read More
View Announcement (PDF)
Regulatory Notice, RNS Announcements | 7 Jul 2020

Notification of Dilution of Voting Rights
London: Tuesday, July 7, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) was notified that CK Hutchison Holdings Limited (“CK Hutchison”) shareholding1 in Chi-Med remains unchanged, at 332,478,770 ordinary shares of par v
Read More
View Announcement (PDF)
Regulatory Notice, RNS Announcements | 29 Jun 2020

Blocklisting Six Monthly Return
London: Monday, June 29, 2020: Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return:   1. Name of applicant: Hutchison China MediTech Limite
Read More
View Announcement (PDF)
Group, RNS Announcements | 26 Jun 2020

Chi-Med to Announce 2020 Half-Year Financial Results
London: Friday, June 26, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) will be announcing its interim results for the six months ended June 30, 2020 on Thursday, July 30, 2020 at 12:00 noon British Summer Time (BST) (7:00 p
Read More
View Announcement (PDF)
Group, RNS Announcements | 25 Jun 2020

Chi-Med Announces US$100 Million Equity Investment by General Atlantic
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   – Strategic investment demonstrates General Atlant
Read More
View Announcement (PDF)
Innovation Platform, Press Releases, RNS Announcements | 18 Jun 2020

Chi-Med Announces Fruquintinib Granted U.S. FDA Fast Track Designation for Metastatic Colorectal Cancer
London: Thursday, June 18, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Designation for the development of fruquintinib, for th
Read More
Download Press Release (PDF)
Commercial Platform, Press Releases, RNS Announcements | 9 Jun 2020

Chi-Med Announces US$95 million Guangzhou Land Compensation Agreement
London: Tuesday, June 9, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited (“HBYS”), its 50:50 joint venture with Guangzhou Baiyu
Read More
Download Press Release (PDF)
Innovation Platform, Press Releases, RNS Announcements | 4 Jun 2020

Chi-Med Announces the Continuation of Phase III FRUTIGA Study of Fruquintinib in Second-Line Gastric Cancer in China Following a Planned Interim Data Review
London: Thursday, June 4, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that the Independent Data Monitoring Committee (IDMC) of the FRUTIGA study of fruquintinib has completed a planned interim data review.
Read More
Download Press Release (PDF)
Corporate presentations, Event, Presentations | 1 Jun 2020

ASCO Investor Update
Press release released:  May 29, 2020 (Fri) >> See press release here Presentation webcast & call:  June 1, 2020 (Mon) 1pm GMT/ 8am EDT/ 8pm HKT >> Click here for the webcast replay  
Read More
Download Presentation (PDF)
Innovation Platform, Press Releases, RNS Announcements | 1 Jun 2020

Chi-Med Plans to Submit NDA for Surufatinib Following Pre-NDA Meeting with the U.S. FDA
London: Monday June 1, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that it has held its pre-New Drug Application (“NDA”) meeting with the U.S. Food and Drug Administration (“FDA”) for surufatinib f
Read More
Download Press Release (PDF)
Innovation Platform, Press Releases, RNS Announcements | 29 May 2020

Chi-Med Announces NDA Acceptance in China for Savolitinib in the Treatment of Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations
Press Release   — First NDA filing of savolitinib globally — —  Chi-Med seeking first-in-class Chinese marketing authorization for a selective MET inhibitor —   London: Friday, May 29, 2020: Hutchison China MediTech Limi
Read More
Download Press Release (PDF)
Innovation Platform, Press Releases, RNS Announcements | 29 May 2020

Chi-Med to Discuss Select Global Clinical Trial Data Presented at ASCO20
Press Release   ― Savolitinib in MET exon 14 skipping NSCLC efficacy evaluable patients demonstrated 49.2% ORR, 93.4% DCR and 9.6 months DoR, including 36% patients with more aggressive disease subtype ― ― Savolitinib vs. sunitinib stu
Read More
Download Press Release (PDF)
Innovation Platform, Press Releases, RNS Announcements | 26 May 2020

Chi-Med and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of Surufatinib and Fruquintinib with Tislelizumab
Press Release   – Collaboration to explore multiple solid tumor cancer indications – – Initial development focused on multi-cohort trials in the U.S., Europe, China and Australia –   LONDON, UK; CAMBRIDGE, Mass. and BEIJING
Read More
Download Press Release (PDF)
Innovation Platform, Press Releases, RNS Announcements | 14 May 2020

Chi-Med Highlights Clinical Data to be Presented at the Upcoming ASCO20 Virtual Scientific Program
London: Thursday, May 14, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that new and updated analyses on the ongoing studies of savolitinib, surufatinib, and fruquintinib will be presented at the upcoming AS
Read More
Download Press Release (PDF)
Group, RNS Announcements | 11 May 2020

Chi-Med to Attend Upcoming Investor Conferences
London: Monday, May 11, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that Mr Christian Hogg, Chief Executive Officer of Chi-Med, will participate in a virtual fireside chat at the Bank of America 2020 Healt
Read More
Download Press Release (PDF)
Regulatory Notice, RNS Announcements | 29 Apr 2020

Grant of Share Options under Share Option Scheme
London: Wednesday, April 29, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) announces that on April 28, 2020, in accordance with its new incentive policy outlined in its full year results announcement on March 3, 2020, it gr
Read More
View Announcement (PDF)
Presentations, Scientific Publications | 27 Apr 2020

AACR2020: Comparison of Pharmacokinetic Profiles and Safety of Surufatinib in Patients from China and the United States
Title: Comparison of Pharmacokinetic Profiles and Safety of Surufatinib in Patients from China and the United States Presenter: Arvind Dasari Authors: A Dasari1, S Paulson2, E Hamilton3, J Wang4, M Sung5, G Falchook6, C Tucci7, K
Read More
Download Presentation (PDF)
Presentations, Scientific Publications | 27 Apr 2020

AACR2020: A Phase I Trial of Surufatinib plus Toripalimab in Patients with Advanced Solid Tumor
Title: A Phase I Trial of Surufatinib Plus Toripalimab in Patients with Advanced Solid Tumors Presenter: Yanshuo Cao Authors: M Lu1, Y Cao1, J Gong1, Y Sun2, J Li1, L Shen1. 1 Department of Gastrointestinal Oncology, Key Labor
Read More
Download Presentation (PDF)
Regulatory Notice, RNS Announcements | 27 Apr 2020

Results of Annual General Meeting
London: Monday, April 27, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that all ordinary resolutions and special resolutions put to its Annual General Meeting (“AGM”) held on April 27, 2020 were duly pa
Read More
View Announcement (PDF)
Innovation Platform, Press Coverage, RNS Announcements | 22 Apr 2020

Chi-Med Highlights Presentations of Surufatinib at the Upcoming AACR Virtual Annual Meetings
London: Wednesday, April 22, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that new and updated analyses on the ongoing studies of surufatinib will be presented at the upcoming American Association for Cance
Read More
Download Press Release (PDF)
Regulatory Notice, RNS Announcements | 21 Apr 2020

Grant of Awards under Long Term Incentive Plan and Share Options under Share Option Scheme
London: Tuesday, April  21, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) announces that on April  20, 2020, in accordance with the new incentive policy outlined in its full year results announcement on March 3, 2020, it
Read More
View Announcement (PDF)
Innovation Platform, Press Releases, RNS Announcements | 17 Apr 2020

Chi-Med Announces Surufatinib Granted U.S. FDA Fast Track Designations for the Treatment of Both Pancreatic and Non-Pancreatic Neuroendocrine Tumors
London: Friday, April 17, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that the U.S. Food and Drug Administration (“FDA”) has granted two Fast Track Designations for the development of surufatinib, for
Read More
Download Press Release (PDF)
Innovation Platform, Press Releases, RNS Announcements | 31 Mar 2020

Chi-Med Initiates a Phase II Trial of HMPL-453 in Patients with Advanced Malignant Mesothelioma in China
London: Tuesday, March 31, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) has initiated a Phase II study of HMPL-453, its novel small molecule inhibitor targeting fibroblast growth factor receptors (“FGFR”), in patients
Read More
Download Press Release (PDF)
Group, RNS Announcements | 25 Mar 2020

2019 Annual Report and Notice of Annual General Meeting
London: Wednesday, March 25, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/ AIM: HCM) today announces that its 2019 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy (“AGM Materials”) have bee
Read More
View Announcement (PDF)
Presentations, Scientific Publications | 13 Mar 2020

ENETS 2020 : Safety Profile and AESI for Surufatinib in Chinese Patients with Advanced Extra-Pancreatic Neuroendocrine Tumors: Analysis of the Phase 3 SANET-ep Trial
The previously reported SANET-ep trial (clinicaltrials.gov identifier NCT02588170) demonstrated that surufatinib significantly improves progression-free survival (“PFS”) in patients with advanced extrapancreatic (non-pancreatic) neuroendocrine tu
Read More
View Poster
Regulatory Notice, RNS Announcements | 9 Mar 2020

Vesting of awards under the Long Term Incentive Plan
London: Monday, March 9, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) announces that following the announcement of the 2019 annual results of Chi-Med on March 3, 2020, the following awards granted under the Long Term Incen
Read More
View Announcement (PDF)
Corporate presentations, Event, Presentations | 3 Mar 2020

2019 Full Year Results
Announcement released: 12 noon GMT (7am EST / 8pm HKT )  >> See announcement here Presentation webcast & call: 1pm GMT (8am EST / 9pm HKT) >> Click here for the webcast replay To participate by phon
Read More
Download Presentation (PDF)
Group, RNS Announcements | 3 Mar 2020

Chi-Med Reports 2019 Full Year Results and Provides Updates on Key Clinical Programs
Company to Host Annual Results Conference Call Today at 1:00 p.m. GMT / 8:00 a.m. EST / 9:00 p.m. HKT   London: Tuesday, March 3, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM), a commercial-stage biopharmaceutical comp
Read More
View Announcement (PDF)
Group, RNS Announcements | 25 Feb 2020

Chi-Med to announce 2019 Final Results on Tuesday, March 3, 2020 – adjustment to announcement and presentation logistics due to travel restrictions
London: Tuesday, February 25, 2020: Further to its announcement dated January 31, 2020, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced that its final results for the year ended December 31, 2019 will be released on Tuesd
Read More
View Announcement (PDF)
Innovation Platform, Press Releases, RNS Announcements | 10 Feb 2020

Chi-Med Highlights Updated Phase II Savolitinib / Imfinzi® Combination Data in Advanced Papillary Renal Cell Carcinoma at 2020 ASCO Genitourinary Cancers Symposium
Press Release London: Monday, February 10, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announced the availability of updated results from the Phase II CALYPSO study of the savolitinib / Imfinzi® (durvalumab) combi
Read More
Download Press Release (PDF)
1
2345678910111213